BR112017002422A2 - domínio de ligação a cd3 - Google Patents

domínio de ligação a cd3

Info

Publication number
BR112017002422A2
BR112017002422A2 BR112017002422A BR112017002422A BR112017002422A2 BR 112017002422 A2 BR112017002422 A2 BR 112017002422A2 BR 112017002422 A BR112017002422 A BR 112017002422A BR 112017002422 A BR112017002422 A BR 112017002422A BR 112017002422 A2 BR112017002422 A2 BR 112017002422A2
Authority
BR
Brazil
Prior art keywords
sequence
chain variable
variable domain
binding domain
represented
Prior art date
Application number
BR112017002422A
Other languages
English (en)
Other versions
BR112017002422B1 (pt
Inventor
Zhukovsky Eugene
Mcaleese-Eser Fionnuala
FUCEK Ivica
ELLWANGER Kristina
Eser Markus
Little Melvyn
Weichel Michael
KNACKMUSS Stefan
Reusch Uwe
Original Assignee
Affimed Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2014/002177 external-priority patent/WO2015018527A1/en
Application filed by Affimed Gmbh filed Critical Affimed Gmbh
Publication of BR112017002422A2 publication Critical patent/BR112017002422A2/pt
Publication of BR112017002422B1 publication Critical patent/BR112017002422B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

a presente invenção se refere a um local de ligação de cd3 humanizado, que compreende (a) um domínio variável de cadeia pesada (vh) como representado na seq id no: 8 e um domínio variável de cadeia leve (vl) como representado na seq id no: 3; ou (b) um domínio variável da cadeia pesada (vh) como representado na seq id no: 9 e um domínio variável da cadeia leve (vl), tal como defenido na seq id no: 4. os locais de ligação de cd3 têm uma estabilidade aumentada, enquanto a afinidade de ligação foi retida devido a mutações nas posições vh111 e vl49.
BR112017002422-5A 2014-08-07 2015-08-05 Domínio de ligação a cd3 BR112017002422B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/EP2014/002177 WO2015018527A1 (en) 2013-08-07 2014-08-07 ANTIBODY BINDING SITES SPECIFIC FOR EGFRvIII
EPPCT/EP2014/002177 2014-08-07
EP15154772.6 2015-02-11
EP15154772.6A EP2982693A1 (en) 2014-08-07 2015-02-11 CD3 binding domain
PCT/EP2015/068070 WO2016020444A1 (en) 2014-08-07 2015-08-05 Cd3 binding domain

Publications (2)

Publication Number Publication Date
BR112017002422A2 true BR112017002422A2 (pt) 2017-11-28
BR112017002422B1 BR112017002422B1 (pt) 2024-02-20

Family

ID=52468915

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017002422-5A BR112017002422B1 (pt) 2014-08-07 2015-08-05 Domínio de ligação a cd3

Country Status (14)

Country Link
US (1) US10066015B2 (pt)
EP (2) EP2982693A1 (pt)
JP (1) JP6669722B2 (pt)
CN (1) CN107001468B (pt)
AU (1) AU2015299039B2 (pt)
BR (1) BR112017002422B1 (pt)
CA (1) CA2957462C (pt)
DK (1) DK3177646T3 (pt)
HR (1) HRP20202024T1 (pt)
HU (1) HUE051919T2 (pt)
LT (1) LT3177646T (pt)
RU (1) RU2742691C2 (pt)
SI (1) SI3177646T1 (pt)
WO (1) WO2016020444A1 (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20160724A1 (es) 2013-11-04 2016-08-04 Glenmark Pharmaceuticals Sa Produccion de inmunoglobulinas heterodimericas de redireccionamiento de celulas t
US11773166B2 (en) 2014-11-04 2023-10-03 Ichnos Sciences SA CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
MX2018002226A (es) 2015-08-28 2018-03-23 Amunix Operating Inc Ensamble de polipeptido quimerico y metodos para hacer y usar el mismo.
EP3371311B1 (en) 2015-11-06 2021-07-21 Orionis Biosciences BV Bi-functional chimeric proteins and uses thereof
JP7325186B2 (ja) 2015-12-09 2023-08-14 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗薬物抗体の形成を減少させるためのｉｉ型抗ｃｄ２０抗体
JP7166923B2 (ja) 2016-02-05 2022-11-08 オリオニス バイオサイエンシズ ビーブイ 標的療法剤およびその使用
EP3252078A1 (en) 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
TW201902512A (zh) 2016-06-02 2019-01-16 瑞士商赫孚孟拉羅股份公司 治療方法
WO2018054484A1 (en) * 2016-09-23 2018-03-29 Biontech Ag Bispecific trivalent antibodies binding to claudin 6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases
WO2018144999A1 (en) 2017-02-06 2018-08-09 Orionis Biosciences, Inc. Targeted engineered interferon and uses thereof
EP3366704A1 (en) 2017-02-28 2018-08-29 Affimed GmbH Antibodies specific for mmp1/hla-a2 complex
EP3619235A1 (en) 2017-04-11 2020-03-11 Inhibrx, Inc. Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
EP3409322A1 (en) 2017-06-01 2018-12-05 F. Hoffmann-La Roche AG Treatment method
JP7247110B2 (ja) * 2017-06-05 2023-03-28 ヌマブ セラピューティクス アクチェンゲゼルシャフト 新規抗ｃｄ３抗体
WO2018224441A1 (en) * 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-cd3 antibodies
EP3668898B1 (en) 2017-08-14 2023-07-05 MorphoSys AG Humanized antibodies for cd3
KR101973060B1 (ko) * 2017-10-20 2019-04-26 주식회사 녹십자 항-cd3 항체 및 이를 포함하는 암 치료용 약학적 조성물
EP3502140A1 (en) * 2017-12-21 2019-06-26 F. Hoffmann-La Roche AG Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules
WO2019160007A1 (ja) 2018-02-14 2019-08-22 中外製薬株式会社 抗原結合分子および組合せ
WO2019175658A1 (en) * 2018-03-14 2019-09-19 Novimmune Sa Anti-cd3 epsilon antibodies and methods of use thereof
JOP20200302A1 (ar) * 2018-05-24 2020-11-23 Janssen Biotech Inc الأجسام المضادة لـ cd3 واستخداماتها
WO2020041537A1 (en) * 2018-08-23 2020-02-27 Regeneron Pharmaceuticals, Inc. Anti-fc epsilon-r1 alpha (fcer1a) antibodies, bispecific antigen-binding molecules that bind fcer1a and cd3, and uses thereof
SG11202109884WA (en) * 2019-03-29 2021-10-28 Green Cross Corp Fusion protein comprising anti-mesothelin antibody, anti-cd3 antibody or anti-egfr antibody, bispecific or trispecific antibody comprising same, and uses thereof
TW202140561A (zh) * 2020-02-14 2021-11-01 日商協和麒麟股份有限公司 與cd3結合之雙特異性抗體
AU2021443863A1 (en) 2021-04-30 2023-10-26 F. Hoffmann-La Roche Ag Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody
EP4330282A1 (en) 2021-04-30 2024-03-06 F. Hoffmann-La Roche AG Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
AR126161A1 (es) 2021-06-17 2023-09-27 Boehringer Lngelheim Int Gmbh Moléculas de fijación triespecíficas novedosas
CN116375868A (zh) * 2021-12-31 2023-07-04 康源博创生物科技(北京)有限公司 一种抗cd3的人源化抗体及其在制备双特异性抗体中的应用
TW202346365A (zh) 2022-03-23 2023-12-01 瑞士商赫孚孟拉羅股份公司 抗ｃｄ２０／抗ｃｄ３雙特異性抗體及化學療法之組合治療
WO2023198727A1 (en) 2022-04-13 2023-10-19 F. Hoffmann-La Roche Ag Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1297090B1 (it) * 1997-12-01 1999-08-03 Barbara Ensoli Tat di hiv-1 o suoi derivati, da soli od in combinazione, a scopo vaccinale, profilattico e terapeutico, contro l'aids i tumori e le
EP1881070B1 (en) * 1999-03-09 2012-10-03 Zymogenetics, Inc. Human cytokine as ligand of the zalpha receptor and uses thereof
ES2276735T3 (es) 2001-09-14 2007-07-01 Affimed Therapeutics Ag Anticuerpos fv multimericos de cadena sencilla en tandem.
SI1716178T1 (sl) 2004-02-16 2010-11-30 Micromet Ag Manj imunogene vezne molekule
PL2612868T3 (pl) * 2007-11-01 2018-12-31 Astellas Pharma Inc. Immunosupresyjne polipeptydy i kwasy nukleinowe
TWI653333B (zh) 2010-04-01 2019-03-11 安進研究（慕尼黑）有限責任公司 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
WO2012133782A1 (ja) * 2011-03-30 2012-10-04 中外製薬株式会社 抗原結合分子の血漿中滞留性と免疫原性を改変する方法
SG195072A1 (en) * 2011-05-21 2013-12-30 Macrogenics Inc Cd3-binding molecules capable of binding to human and non-human cd3
US9915665B2 (en) * 2012-12-28 2018-03-13 Abbvie Inc. High-throughput system and method for identifying antibodies having specific antigen binding activities
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
EP2948475A2 (en) 2013-01-23 2015-12-02 AbbVie Inc. Methods and compositions for modulating an immune response
EP3030581B1 (en) * 2013-08-07 2021-01-20 Affimed GmbH Antibody binding sites specific for egfrviii
US9212225B1 (en) * 2014-07-01 2015-12-15 Amphivena Therapeutics, Inc. Bispecific CD33 and CD3 binding proteins

Also Published As

Publication number Publication date
JP2017529067A (ja) 2017-10-05
CN107001468A (zh) 2017-08-01
BR112017002422B1 (pt) 2024-02-20
RU2017105120A (ru) 2018-09-10
RU2017105120A3 (pt) 2019-02-20
RU2742691C2 (ru) 2021-02-09
AU2015299039A1 (en) 2017-03-02
SI3177646T1 (sl) 2021-04-30
HUE051919T2 (hu) 2021-04-28
EP3177646B1 (en) 2020-10-07
HRP20202024T1 (hr) 2021-02-19
CN107001468B (zh) 2021-04-09
WO2016020444A1 (en) 2016-02-11
DK3177646T3 (da) 2020-12-07
LT3177646T (lt) 2021-01-11
EP3177646A1 (en) 2017-06-14
JP6669722B2 (ja) 2020-03-18
AU2015299039B2 (en) 2021-01-21
CA2957462C (en) 2023-10-17
CA2957462A1 (en) 2016-02-11
US10066015B2 (en) 2018-09-04
EP2982693A1 (en) 2016-02-10
US20160039934A1 (en) 2016-02-11

Similar Documents

Publication Publication Date Title
BR112017002422A2 (pt) domínio de ligação a cd3
BR112016024780A2 (pt) composições e métodos relacionados com construtos de fc manipulados
CY1122398T1 (el) Συνδυαστικες θεραπειες με αντισωματα anti-cd38
CU20190109A7 (es) Moléculas de anticuerpo que se unen a cd73
BR112018074032A2 (pt) composições e métodos relacionados a construtos de fc manipulados
CO2018000104A2 (es) Moléculas de anticuerpo que se unen a cd22
CO2018011364A2 (es) Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos
CL2016002455A1 (es) Anticuerpos multiespecíficos.
ECSP18023386A (es) Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas
CO2018002446A2 (es) Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas
EA201791485A1 (ru) Анти-cd47-антитела и их применения
BR112017001579A2 (pt) anticorpos anti-cd3, anticorpos anti-cd3 ativáveis, anticorpos anti-cd3 multiespecíficos, anticorpos anti-cd3 ativáveis multiespecíficos e métodos de uso dos mesmos
CR20160425A (es) Moléculas de anticuerpos que se unen a lag-3 y usos de las mismas
EA201691272A1 (ru) Тетрагидропиридопиразины в качестве модуляторов gpr6
UA122479C2 (uk) Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
EA201700546A1 (ru) Композит полипропилен - углеродное волокно
EA201790173A1 (ru) Антитела, связывающие axl
CY1124425T1 (el) Συνθεσεις οι οποιες περιλαμβανουν συζευγματα φαρμακου αντισωματος-δουοκαρμυκινης
EA201700547A1 (ru) Армированная волокнами полимерная композиция
BR112017005266A2 (pt) inibidores de mk2 e uso dos mesmos
BR112018015754A2 (pt) anticorpos anti-tnf, composições, métodos e uso para o tratamento ou prevenção de diabetes tipo 1
EP3896054A3 (de) Fluorverbindungen
BR112016014731A2 (pt) Anticorpos anti-baff
BR112016018313A8 (pt) Moléculas de ligação multiespecíficas iga
MA42049A (fr) Sulfones tricycliques utiles commes modulateurs ror-gamma

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/08/2015, OBSERVADAS AS CONDICOES LEGAIS